NEW YORK--(BUSINESS WIRE)--
Medidata (MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced the company’s participation in the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 in New York. Glen de Vries, co-founder and president, will participate on a panel discussing “Artificial Intelligence (AI) Applications in Healthcare.” Rouven Bergmann, chief financial officer, will participate in a fireside chat at 11:00 a.m. ET.
A live audio webcast of Mr. Bergmann’s discussion will be available on the “Investor” section of Medidata’s website at http://investor.mdsol.com. Please visit the website at least 15 minutes prior to the event to register, download and install any necessary audio or video software to access the presentation. For those unable to participate in the live webcast, a replay will be archived on the “Investor” section of Medidata’s website at http://investor.mdsol.com for a limited period of time following the conference.
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 950 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.